RVNC News and Press, Revance Therapeutics Inc. From 01/08/24

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 m...

2023-12-25 02:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...

2023-11-29 12:06:50 ET Summary Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of Daxxify - approved to treat frown lines, and recently a...

2023-11-14 17:52:57 ET More on Revance Therapeutics Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn Revance's FDA Nod: Beauty, Brains, And Balance Sheets Needham says Abbvie...

2023-11-08 22:50:20 ET Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Conference Call November 08, 2023, 04:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO ...

2023-11-08 16:23:27 ET Revance Therapeutics press release ( NASDAQ: RVNC ): Q3 GAAP EPS of -$1.63 misses by $0.69 . Revenue of $56.8M (+95.9% Y/Y) misses by $1.94M . Expects its 2023 GAAP operating expenses to be $545 million to $585 million. Cash, cash equ...

– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. – Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. – Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%. – In Augus...

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility for all aesthetics commercial activity including commercial strategy, sales a...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...